Totally implantable vascular access devices for cystic fibrosis

Cochrane Database of Systematic Reviews, 2012

Totally implantable vascular access devices for cystic fibrosis - The Cochrane Library - A‐Rahman - Wiley Online Library from LOGIN Enter e-mail address Enter password REMEMBER ME > > > > DATABASE TOOLS DATABASE MENU FIND ARTICLES OTHER RESOURCES Intervention Review You have full text access to this content Totally implantable vascular access devices for cystic fibrosis Amel KM A‐Rahman 1,* , David Spencer 2 Editorial Group: Published Online: 16 MAY 2012 Assessed as up-to-date: 10 APR 2012 DOI: 10.1002/14651858.CD004111.pub2 Copyright © 2012 The Cochrane Collaboration.
Publication History Publication Status: New search for studies and content updated (no change to conclusions) Published Online: 16 MAY 2012 SEARCH ARTICLE TOOLS Abstract Abstract Background Totally implantable vascular access devices are widely used in people with cystic fibrosis to provide intermittent venous access for therapeutic infusions.
Objectives To assess if totally implantable venous access devices provide a safe and effective route for venous access for intermittent administration of intravenous antibiotics in people with cystic fibrosis.
Also to assess strategies to reduce possible complications of totally implantable venous access devices (e.g.
Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings.
Selection criteria Randomised and quasi-randomised controlled trials which compared the use of totally implantable venous access devices in people with cystic fibrosis to other means of vascular access, trials which compared the different types of these devices against each other and trials which assessed strategies to reduce complications of these devices.
Authors' conclusions Totally implantable vascular access devices are widely used in people with cystic fibrosis to provide intermittent venous access for therapeutic infusions.
These reports also suggest that certain interventions might reduce the risk of complications; however, it is disappointing that these reports have not been assessed by randomised controlled trials.
This systematic review identifies the need for a multicentre randomised controlled trial assessing both efficacy and possible adverse effects of totally implantable venous access devices in cystic fibrosis.
Plain language summary A tube fitted inside a vein to allow drug injections for people with cystic fibrosis Cystic fibrosis blocks the lungs with mucus and causes frequent infections and lung damage.
Infections are often treated by giving drugs intravenously (through a vein), but regular injections can damage veins.